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background:  Delayed healing and incomplete endothelialization have been reported with durable polymer drug-eluting stents (DES); 
these may contribute to increased risk of late/very late stent thrombosis (ST) and a need for prolonged dual antiplatelet therapy. The 
SYNERGY everolimus-eluting stent (EES; Boston Scientific Corporation, Marlborough, MA), designed to reduce stent thrombosis risk, 
consists of a thin-strut, platinum chromium metal alloy platform abluminally-coated with an ultrathin bioabsorbable poly(DL-lactide-co-
glycolide) polymer. Drug release and polymer absorption are complete within 4 months. The EVOLVE II QCA trial evaluated angiographic 
outcomes with SYNERGY; this is the first report of 9 month QCA outcomes with the SYNERGY stent.
methods:  EVOLVE II QCA is a prospective, single-arm, multicenter study. Patients enrolled had de novo atherosclerotic coronary artery 
lesions ≤34 mm in length and diameter ≥2.25 mm to ≤4.50 mm. Patients were ≥18 years old with silent ischemia or symptomatic coronary 
artery disease with objective evidence of ischemia. Up to 3 native coronary artery lesions in 2 major epicardial vessels could have been 
treated. Exclusion criteria included STEMI and complex lesion morphology. The primary endpoint is in-stent late loss at 9 months post-
procedure (independent core lab assessment).
results:  Subjects (N=100) were enrolled at 12 clinical sites in Australia, New Zealand, Singapore, and Japan between March 25 - October 
15, 2013 Mean age was 64 years, 20% of patients were female, and 17% of patients had medically-treated diabetes mellitus. Baseline 
RVD was 2.66±0.46 mm; lesion length was 14.38±7.49 mm. In-stent late loss at 9-months (the primary endpoint) was 0.23±0.34 mm, 
significantly below the prespecified performance goal of 0.4 mm (P<0.01). Net volume obstruction was 5.19±5.67%. To 9-months, there 
were no deaths or ST. Five patients had peri-procedural non-Q-wave MI (primarily defined as CK-MB>5x ULN; mean CK-MB 29.0±14.44 
ng/mL) and 1 patient had a target lesion revascularization.
Conclusion:  Through 9-months, SYNERGY had an acceptable safety profile with low in-stent late loss. One-year results will be available 
for presentation at ACC 2015.
